FDA Drugs recall ·
Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg)… recall
- Recall number
- D-0135-2025
- Date
- (initiated November 19, 2024)
- Company / brand
- Mylan Institutional, Inc.
1718 Northrock Ct, Rockford, IL, United States - Category
- Drugs › Class II
- Classification
- Class II
- Status
- Ongoing
- Units affected
- 690 cartons
- Hazard tags
- Potency
- Initiated by
- Voluntary: Firm initiated
Read the official FDA notice ↗
Product
Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-445-20
Why was it recalled?
Subpotent and Superpotent Drug
What should you do?
FDA enforcement reports do not list a consumer remedy. Check the product codes below against what you have; if it matches, stop using it and follow the instructions in the firm's or FDA's official notice, or contact the company. If you have health concerns, contact your healthcare provider.
Product codes & lot numbers
Lot #: 3115924, Exp. Date 06/2025
Distribution
Nationwide in the USA.
What does Class II mean?
Class II means use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or the probability of serious harm is remote.
Source: FDA (drugs), recall D-0135-2025. Official notice. Republished from public data; RecallFlag is not affiliated with the FDA.